Healthcare
Live Price
Offline$2.35
-0.21% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Augmedix, Inc. (AUGX) is a Healthcare stock with a market cap of $115.91M. The stock last traded around $2.35. Baseline metrics include revenue growth of +45.0%, EPS growth of +38.0%, a dividend yield of 0.0%. What stands out right now is revenue +45.0%, EPS +38.0%, free cash flow -2.0% with operating margin -41.9% and ROIC -36.8%. Valuation is more restrained than many high-expectation growth names at price/sales 2.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines AUGX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
AUGX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
AUGX Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for AUGX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$14.1M
-14.4% YoY
FY Net Income
-$22.4M
-51.7% YoY
Free Cash Flow
-$15.5M
-2.8% YoY
Revenue Growth
+45.0%
EPS Growth
+38.0%
Gross Margin
48.0%
Net Margin
-42.7%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 45M | 31M | 22M | 16M | 14M |
| Gross Profit | 22M | 14M | 10M | 7M | 5M |
| Operating Income | -19M | -22M | -18M | -14M | -17M |
| EBITDA | -16M | -22M | -14M | -13M | -15M |
| Net Income | -19M | -27M | -17M | -15M | -22M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 46M | 22M | 42M | 21M | 10M |
| Total Assets | 67M | 34M | 52M | 28M | 16M |
| Total Liabilities | 43M | 32M | 28M | 25M | 81M |
| Shareholder Equity | 23M | 1M | 24M | 3M | -65M |
| Total Debt | 27M | 20M | 15M | 15M | 13M |
| Net Debt | -19M | -2M | -27M | -6M | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
15M
-1.7% YoY
Capital Expenditures
823K
-27.2% YoY
Free Cash Flow
15M
-2.8% YoY
Key ratios
Gross Margin
48.0%
Operating Margin
-41.9%
Net Margin
-42.7%
ROE
-154.7%
Debt / Equity
1.17x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.